Your browser doesn't support javascript.
loading
A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa.
Jepsen, Rebecca; Edwards, Chloe; Flora, Akshay; Kozera, Emily; Frew, John W.
Afiliação
  • Jepsen R; Holdsworth House Medical Practice, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Sydney, Australia.
  • Edwards C; Holdsworth House Medical Practice, Sydney, Australia.
  • Flora A; Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Sydney, Australia; Department of Dermatology, Liverpool Hospital, Sydney, Australia; University of New South Wales, Sydney, Australia.
  • Kozera E; Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Sydney, Australia; Department of Dermatology, Liverpool Hospital, Sydney, Australia; University of New South Wales, Sydney, Australia.
  • Frew JW; Holdsworth House Medical Practice, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Sydney, Australia; Department of Dermatology, Liverpool Hospital, Sydney, Australia; University of New South Wales, Sydney, Australia. Electronic addre
J Am Acad Dermatol ; 89(4): 694-702, 2023 10.
Article em En | MEDLINE | ID: mdl-37307994

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Hidradenite Supurativa Limite: Humans Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Hidradenite Supurativa Limite: Humans Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália